Table 4.

Treatment related adverse events according to posttreatment PLC quartile groups.

Posttreatment PLC	Quart1 (n = 58)	Quart2 (n = 58)	Quart3 (n = 58)	Quart4 (n = 57)	P
Adverse event (n = 61)	11 (19.0%)	15 (24.6%)	20 (31.6%)	19(32.1%)	0.30
Pneumonitis	6 (54.6%)	3 (20.0%)	6 (33.3%)	1 (5.3%)	0.43
Skin lesion	1 (9.1%)	2 (13.3%)	4 (20.0%)	3 (15.7%)
Hepatitis	1 (9.1%)	2 (13.3%)	2(10.0%)	2 (10.5%)
TFT abnormality	0 (0.0%)	1 (6.7%)	3 (15.0%)	2 (10.5%)
Arthritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (15.7%)
Fever	0 (0.0%)	0 (0.0%)	1 (5.0%)	2 (10.5%)
Anorexia	0 (0.0%)	2 (13.3%)	1 (5.0%)	1 (5.3%)
Others	3 (27.3%)	5 (33.3%)	3 (15.0%)	5 (26.3%)
Serious adverse event	6 (10.3%)	5 (8.6%)	7 (12.1%)	3 (534%)	0.67